KaloBios Pharmaceuticals Inc: Initiation of Coverage
KaloBios Pharmaceuticals is a biopharmaceutical company focused on the development of monoclonal antibody (mAb) therapeutics. The company utilizes its proprietary Humaneered™ antibody technology platform to convert sub-optimal non-human antibodies into engineered, high-affinity human antibodies.
KaloBios currently advances three early-mid stage clinical stage programs with three different mAbs. In addition, one of the company’s leading clinical programs is licensed to Sanofi Pasteur.
KaloBios recently completed an initial public offering is now trading on the Nasdaq Global Market.
To download this document, fill out your details below. The link to the document will be sent to you when you click ‘Get the Link’.